X0306 4 2019-05-17 1 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574589 Curnutte John T C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP R&D Common Stock 2019-05-17 4 A 0 4688 0.00 A 103227 D Common Stock 2019-05-17 4 A 0 1750 0.00 A 104977 D Common Stock 2019-05-20 4 F 0 2418 28.69 D 102559 D Common Stock 2019-05-20 4 F 0 903 28.69 D 101656 D Performance Stock Unit 2019-05-17 4 M 0 4688 0.00 D 2027-01-30 Common Stock 4688 0 D Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration. Each Performance Stock Unit (PSU) granted March 29, 2018 represented a contingent right to receive one (1) share of Issuer's Common Stock. 1,750 would have vested upon the one year anniversary of the Compensation Committee's certification of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the acceleration. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). /s/ Mike Ouimette, as attorney-in-fact 2019-05-21